DJIA 16,880.36 -31.75 -0.19%
NASDAQ 4,462.90 20.20 0.45%
S&P 500 1,970.07 0.12 0.01%
market minute promo

322.18 17.67 (5.80%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $322.18 5.80%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $328.55
Previous Close $304.51
Daily Range $315.00 - $336.94
52-Week Range $227.64 - $352.49
Market Cap $32.5B
P/E Ratio 87.25
Dividend (Yield) $0.00 (0.0%)
Volume 2,373,719
Average Daily Volume 968,800
Current FY EPS $9.29

Sector

Healthcare

Industry

Drugs

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

Cholesterol-Lowering Drug Market Heats Up

This video discusses Amgen's evolocumab, Rengeneron Pharmaceuticals and Sanofi's alirocumab, and the rest of the PCSK9 inhibitors.

Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog

S&P 500 Movers: GNW, EW

Nasdaq 100 Movers: GRMN, REGN

Jim Cramer's Mad Dash: Good News for Regeneron

Trade-Ideas: Regeneron Pharmaceuticals (REGN) Is Today's Pre-Market Leader Stock

Sanofi And Regeneron Report Positive Top-Line Results From Nine Phase 3 Trials Of Alirocumab In Peop

Sanofi And Regeneron Report Positive Top-Line Results From Nine Phase 3 Trials Of Alirocumab In People With Hypercholesterolemia

3 Stocks Reiterated As A Buy: GM, DD, REGN

Regeneron Pharmaceuticals Inc Stock Upgraded (REGN)

REGN, ILMN And CELG, Pushing Health Care Sector Downward

Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog

See More REGN News...

REGN's Top Competitors

REGN $322.18 (5.80%)
Current stock: REGN
AMGN $130.01 (5.43%)
Current stock: AMGN
GILD $93.79 (0.86%)
Current stock: GILD
BIIB $344.52 (0.82%)
Current stock: BIIB